Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study

American Journal of Hematology

Volumn 88, Issue 1, 2013, Pages 1-4

  Rousselot, Philippe ^a,b   Cony Makhoul, Pascale ^c   Nicolini, Franck ^d   Mahon, François Xavier ^e   Berthou, Christian ^f   Réa, Delphine ^b   Reiffers, Josy ^g   Bornand, Anne ^h   Saint Jean, Olivier ⁱ   Guilhot, Joelle ^j   Guilhot, François ^j  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c Centre Hospitalier de la Region d'Annecy   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f BREST UNIVERSITY HOSPITAL   (France)

^g INSTITUT BERGONIÉ   (France)

^h HÔPITAL CHARLES FOIX   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j POITIERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB;

AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER REGISTRY; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMORBIDITY; CYTOGENETICS; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ELDERLY CARE; FEMALE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; LONG TERM CARE; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; SURVIVAL RATE; TIME FACTORS;

EID: 84871432930     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23330     Document Type: Article

References (22)

1. Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315: 550-554.
2. Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 2009; 22: 295-302.
3. Rohrbacher M, Berger U, Hochhaus A, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009; 23: 602-604.
4. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
5. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
6. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
7. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
8. Miller MD, Towers A. A Manual of Guidelines for Scoring the Cumulative Illness Rating Scale for Geriatrics. Pittsburgh, PA: University of Pittsburgh; 1991.
9. Müller MC, Erben P, Saglio G, et al. European LeukemiaNet. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008; 22: 96-102.
10. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63: 789-799.
11. Cortes J, Kantarjian H, O'Brien S, et al. Result of interferon-α therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 1996; 100: 452-455.
12. Berger U, Engelich G, Maywald O, et al. Chronic myeloid leukemia in the elderly: Long-term results from randomized trials with interferon α. Leukemia 2003; 17: 1820-1826.
13. Cortes J, Talpaz M, O'Brien S, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003; 98: 1105-1113.
14. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
15. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358-3363.
16. Rosti G, Iacobucci I, Bassi S, et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: Results of a phase II study of the GIMEMA CML Working Party. Haematologica 2007; 92: 101-105.
17. Gugliotta G, Castagnetti F, Palandri F, et al. Frontline imatinib treatment of chronic myeloid leukemia: No impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011; 117: 5591-5599.
18. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
19. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
20. Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010; 116: 377-386.
21. Arias E. United States life tables, 2007. Natl Vital Stat Rep 2011; 59: 1-60.
22. Hasford J, Pfirrmann M, Hochhaus A. How long will chronic myeloid leukemia patients treated with imatinib mesylate live? Leukemia 2005; 19: 497-499.